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ABSTRACT
Background A previous case–control study of 100
individuals found that short telomere length was
associated with a 28-fold increased risk of chronic
obstructive pulmonary disease (COPD).
Objectives To test the hypothesis that short telomere
length is associated with reduced lung function and an
increased risk of COPD.
Methods Observational study of 46 396 individuals
from the Danish general population.
Measurements Leucocyte telomere length and
spirometry were measured. COPD was deﬁned using either
ﬁxed forced expiratory volume in 1 s (FEV1)/forced vital
capacity (FVC) ratio <0.70 as suggested by the Global
initiative for chronic Obstructive Lung Disease (GOLD) or
FEV1/FVC below the lower limit of normal (LLN).
Results Telomere length decreased signiﬁcantly with
increasing age (p<10−300). FEV1, FVC and FEV1/FVC
decreased with decreasing telomere length quartiles
(p trend: 5×10−51, 5×10−35 and 6×10−137, respectively),
but the associations attenuated after age and multivariable
adjustment. The risk of COPD increased with decreasing
telomere length quartile (p trend: p=7×10−92 for GOLD;
p=8×10−44 for FEV1/FVC below LLN), but associations
also attenuated after adjustment. Unadjusted and
multivariable adjusted OR for shortest versus longest
telomere length quartiles were 2.06 (95% CI 1.91 to 2.22)
and 1.15 (95% CI 1.06 to 1.25) for GOLD and 1.73 (95%
CI 1.60 to 1.88) and 1.19 (95% CI 1.09 to 1.30) for FEV1/
FVC below LLN, respectively. Per 1000 base pairs decrease
in telomere length, the multivariable adjusted OR was 1.07
(95% CI 1.03 to 1.10) for GOLD and 1.07 (95% CI 1.03
to 1.11) for FEV1/FVC below LLN.
Conclusions Short telomere length is associated with
decreased lung function and with increased risk of COPD,
but the associations are markedly attenuated after
adjustment. Our data support a modest correlation
between telomere length and the lung function indices
examined.
INTRODUCTION
Lung tissue is often exposed to oxidants from
inhaled nitrogen dioxide, ozone, gasoline and
diesel exhaust and from tobacco smoke. The com-
bination of a large surface area and a high blood
supply result in a high susceptibility to oxidative
stress in lung tissue,1 a factor that is believed to
play a crucial role in pulmonary inﬂammation,
decreased pulmonary function and in the develop-
ment of chronic obstructive pulmonary disease
(COPD).
Telomeres are repetitive DNA sequences at the
end of chromosomes which are important for
chromosome protection and thus for longevity of
cells.2 3 In most cells telomere length shortens with
each cell division, and since exposure to oxidative
stress as well as inﬂammation enhance this shorten-
ing, telomere length may serve as a marker for cel-
lular ageing.4 5 In accordance with this notion,
telomere length decreases with increasing age, and
short telomere length is also associated with life-
style factors such as smoking, obesity and stress.6–9
It is therefore plausible that pulmonary oxidative
stress and inﬂammation could lead to short telo-
mere length, and that short telomere length could
be a marker of decreased lung function and
increased risk of COPD.
Key messages
What is the key question?
▸ Are shorter telomeres associated with reduced
lung function and increased risk of chronic
obstructive pulmonary disease (COPD)?
What is the bottom line?
▸ It is biologically plausible that pulmonary
oxidative stress and inﬂammation could lead to
short telomere length and, hence, short
telomere length could be a marker of
decreased lung function and increased risk of
COPD.
▸ Among 46 396 individuals, those with short
telomeres are more likely to have reduced lung
function and COPD, according to the GOLD
classiﬁcation as well as according to forced
expiratory volume in 1 s/forced vital capacity
below lower limit of normal, compared with
those with long telomeres.
Why read on?
▸ This very large study shows that short telomere
length is associated with COPD risk. The
association may, however, be more moderate
than previously suggested in smaller studies of
76–291 individuals.
▸ Our results stress the importance of adjusting
for age and other confounders when examining
the association between COPD and short
telomeres.
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We tested the hypothesis that short telomere length is asso-
ciated with decreased lung function and increased risk of COPD
in a sample of 46 396 participants from the Danish general
population. Severity of COPD was deﬁned according to forced
expiratory volume in 1 s (FEV1) and forced vital capacity
(FVC), either by the Global initiative for chronic Obstructive
Lung Disease (GOLD) criteria or by FEV1/FVC below the lower
limit of normal (LLN).10 11
METHODS
Population
We studied participants from the Copenhagen General
Population Study and the Copenhagen City Heart Study, both
of which are Danish prospective general population studies.12–14
In both studies, randomly selected Copenhagen residents were
invited to complete a questionnaire and undergo a physical
examination including spirometry. Whole blood samples were
collected for DNA isolation. There was no overlap of indivi-
duals between the two studies.
The study population consisted of 37 355 participants from
the Copenhagen General Population Study included between
2003 and 2007 and 9041 participants from the Copenhagen
City Heart Study included between 1991 and 1994, all with
available spirometry and telomere length measurement. A total
of 16 563 individuals were invited to participate in The
Copenhagen City Heart Study between 1991 and 1994 and of
those 10 135 entered the study. Whole blood samples for DNA
isolation were collected in 9252 individuals, and among these
9041 had information on telomere length and spirometry. The
Copenhagen General Population Study is an ongoing study. A
total of 46% of invited individuals participated and 99% had
whole blood samples collected for DNA isolation. Spirometry
data are available for 98% of participants.
Lung function and COPD
At each examination three sets of values were registered for
FEV1 and FVC and the highest set of values was used in the
analyses. At least two measurements of FEV1 and FVC with a
difference of less than 5% had to be obtained to ensure correct
performance of the procedure. In the Copenhagen General
Population Study, two different spirometers were used, a dry
wedge spirometer in the ﬁrst 15 000 participants and an
EasyOne Spirometer in the rest of the population. In the
Copenhagen City Heart Study, a dry wedge spirometer was
used. Details regarding instruments have been described
elsewhere.12 15 16
Predicted values for FEV1 and FVC were calculated for never
smoking men and women individually using multiple linear
regression analysis with age and height as covariates. Regression
analyses were performed for the two studies individually as well
as for type of spirometer used in the Copenhagen General
Population Study.12 17 LLN for FEV1/FVC was deﬁned as a
ratio below the 5th centile of the predicted ratio for height and
age in never smoking men and women individually, separately
in each study and according to the type of spirometer used.
COPD was deﬁned according to (1) GOLD with FEV1/
FVC<0.70 and degree of airﬂow limitation split in four grades10:
(I) FEV1≥80% predicted, (II) FEV1 50–79% predicted, or (III–IV)
FEV1<50% predicted; and (2) FEV1/FVC below LLN.
11
Individuals aged <40 years with self-reported asthma (n=323)
were omitted from all analyses.
Telomere length
Telomere length was measured in DNA isolated from blood leu-
cocytes. We used a modiﬁed monochrome multiplex quantita-
tive PCR method,18 as described in detail elsewhere.19 In brief,
we used the reference single-copy gene for albumin to adjust for
different amounts of DNA in samples. DNA from each partici-
pant was measured in quadruplicate and the mean of four telo-
mere threshold cycle values and the mean of four albumin
threshold cycle values were calculated. Unsuccessful samples
were analysed again until valid measurements were available in
99.9% of participants. Of these, a telomere length measurement
was obtained after the ﬁrst analysis in 98.4%, whereas 1.1% of
samples were rerun once and 0.5% were rerun twice. The abso-
lute telomere length was derived after calibration with measure-
ment on K562 cell line DNA, included in each plate.
Covariates
The following information was collected from the questionnaires
at inclusion in the studies: age at examination, gender, number of
years in school as well as information on smoking habits, occupa-
tional exposure to dust and fumes (yes/no) and dyspnoea.
Participants were classiﬁed as never smokers, former smokers or
current smokers. For former smokers and current smokers, pack-
years of cigarettes or equivalent smoking were calculated and
information on inhalation was noted as yes/no. One pack-year
corresponds to one pack of 20 cigarettes or equivalent smoked
for a year. The severity of dyspnoea was graded from 0 to 4
according to the modiﬁed Medical Research Council Dyspnoea
Scale.20 Questionnaires were completed and reviewed by an
examiner on the day of examination. Height and weight were
registered on the day of examination. Body mass index was calcu-
lated as the measured weight divided by the square of the mea-
sured height and categorised according to the WHO
classiﬁcation into body mass index <18.5 kg/m2, 18.5–24.9 kg/
m2, 25–29.9 kg/m2 and ≥30 kg/m2. The number of years in
school were categorised as <8 years, 8–11 years and >11 years.
For logistic regression analysis, C-reactive protein levels were
categorised according to lowest, middle and highest tertiles but
used on a continuous scale in other analyses.
Statistical analyses
The association between telomere length continuously with age
and between telomere length quartiles and lung function was
assessed by general linear models while the association with
COPD was assessed by logistic regression. Multivariable models
were adjusted for age, gender, body mass index, smoking status,
smoking inhalation, cumulative smoking in pack-years, occupa-
tional exposure to dust and fumes, years in school, plasma
C-reactive protein levels, grade of dyspnoea and study. Covariates
were more than 99.5% complete; missing values were imputed
according to age, gender and smoking status. For trend tests, indi-
viduals were categorised according to telomere length quartiles
coded 1–4 with the ﬁrst quartile consisting of individuals with the
longest telomere lengths. We tested interaction by using a likeli-
hood ratio test that compared the main effects model with a
model also including a two-factor interaction term. Stata V.12.0
was used for all analyses.
RESULTS
Figure 1 shows the decrease in telomere length on a continuous
scale with increasing age in the 46 396 participants from the
general population (p<1×10−300). Decreasing telomere length
in quartiles was associated with increased age, male gender,
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increased body mass index, former smoking status, smoking
inhalation, increased cumulative smoking, increased occupa-
tional exposure to dust and fumes, <8 years in school and with
increased C-reactive protein levels (table 1). Table 2 shows the
association between telomere length on a continuous scale and
covariates individually and in combination. The strongest asso-
ciations with telomere length in the multivariable analysis were
found for age, gender, cumulative smoking in pack-years and
body mass index.
Decreasing telomere length in quartiles was associated with
decreased FEV1% predicted (p trend: p=5×10
−51), decreased
FVC % predicted (p=5×10−35) and with decreased FEV1/FVC
(p=6×10−137) (ﬁgure 2). FEV1% predicted was 97% in the
ﬁrst quartile, 96% in the second, 95% in the third and 94% in
the fourth quartile of telomere length. Corresponding values for
FVC % predicted were 99%, 98%, 98% and 97%, and for
FEV1/FVC 0.78, 0.78 0.77, and 0.76, respectively. The associ-
ation between decreased telomere length and decreased lung
function was attenuated after age adjustment (p trend:
p=5×10−16 for FEV1% predicted; p=1×10
−12 for FVC % pre-
dicted; p=5×10−5 for FEV1/FVC) and even further after multi-
variable adjustment for age, gender, body mass index, smoking
status, smoking inhalation, cumulative smoking, occupational
exposure to dust and fumes, years in school, C-reactive protein
levels, grade of dyspnoea and study (p trend: p =1×10−6,
p=4×10−5 and p=0.07, respectively).
Similar patterns were seen when analysing telomere length as a
continuous variable (ie, change in lung function per 1000 base
pair decrease in telomere length; ﬁgure 3). Stratiﬁed analyses of
the change in unadjusted FEV1/FVC per 1000 base pair decrease
in telomere length showed a decrease in all strata (ﬁgure 4).
FEV1/FVC decreased slightly more in women than in men, in
individuals aged ≥60 years than in those aged <60 years of age
and in former and current smokers than in never smokers.
A total of 6770 participants (15%) had an FEV1/FVC <0.70.
Among these, 2922 (43%) were classiﬁed as GOLD stage I,
3026 (45%) as GOLD stage II and 822 (12%) as GOLD stages
III–IV. A total of 5136 participants (11%) met the criteria for
COPD by FEV1/FVC below LLN. Table S1 in the online supple-
ment shows the baseline characteristics of participants according
to these COPD criteria.
Figure 5 shows the unadjusted, age adjusted and multivariable
adjusted logistic regression analyses of the association between
decreasing telomere length in quartiles and COPD risk accord-
ing to the GOLD criteria and FEV1/FVC below LLN. In the
unadjusted analyses, the OR of COPD increased with decreasing
telomere length quartiles (p trend: p=7×10−92 for GOLD cri-
teria; p=8×10−44 for FEV1/FVC below LLN). In the
Figure 1 Telomere length in base
pairs by 5-year age groups according
to age at blood sampling. Based on
46 396 participants from the Danish
general population from the
Copenhagen General Population Study
and the Copenhagen City Heart Study.
Table 1 Baseline characteristics of participants by quartiles of telomere length
1st quartile (longest) 2nd quartile 3rd quartile 4th quartile (shortest)
n=11599 n=11600 n=11599 n=11598 p For trend
Telomere length, base pairs 5323 (5007–5842) 4402 (4240–4568) 3821 (3684–3956) 3204 (2950–3387)
Age, years 53 (43–62) 56 (46–65) 60 (50–69) 65 (56–73) <1×10−300
Men, n (%) 5026 (43) 5155 (44) 5433 (47) 5740 (49) 1×10−22
Body mass index, kg/m2 25 (23–28) 26 (23–28) 26 (23–29) 26 (23–29) 5×10−48
Smoking status
Former smoking, n (%) 4236 (37) 4512 (39) 4787 (41) 5121 (44) 3×10−33
Current smoking, n (%) 2857 (25) 2758 (24) 2909 (25) 2841 (25) 0.14
Smoking inhalation, n (% of former or current smokers) 5927 (84) 5909 (81) 6032 (78) 5984 (75) 1×10−39
Cumulative smoking, pack-years 5 (0–22) 6 (0–24) 9 (0–29) 12 (0–32) 4×10−103
Occupational exposure to dust/fumes, n (%) 1499 (13) 1531 (13) 1650 (14) 1766 (15) 4×10−7
<8 years in school, n (%) 1635 (14) 1820 (16) 2289 (20) 2754 (24) 4×10−94
C-reactive protein, mg/l 1.4 (0.8–2.6) 1.5 (1.0–2.6) 1.6 (1.1–2.8) 1.7 (1.2–3.1) 5×10−152
Continuous variables are shown as medians (IQR) and categorical variables are shown as numbers (%).
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unadjusted analyses, OR for the shortest versus the longest telo-
mere quartiles was 2.06 (95% CI 1.91 to 2.22) for GOLD cri-
teria and 1.73 (1.60 to 1.88) for FEV1/FVC below LLN. The
association was markedly attenuated when analyses were
adjusted for age or multivariable adjusted for age, gender, body
mass index, smoking status, smoking inhalation, cumulative
smoking, occupational exposure to dust and fumes, years in
school, C-reactive protein levels, grade of dyspnoea and study.
In the multivariable models the OR for the shortest versus
longest telomere quartiles was 1.15 (95% CI 1.06 to 1.25) for
GOLD criteria and 1.19 (95% CI 1.09 to 1.30) for FEV1/FVC
below LLN. Trend tests across quartiles after multivariable
adjustment yielded p values of 0.001 and 6×10−5, respectively,
for GOLD criteria and FEV1/FVC below LLN.
Per 1000 base pairs decrease in telomere length, the multi-
variable adjusted OR was 1.07 (95% CI 1.03 to 1.10) for
GOLD criteria and 1.07 (1.03 to 1.11) for FEV1/FVC below
LLN (ﬁgure 6). We stratiﬁed according to gender, age, smoking
status and cumulative smoking in multivariable adjusted models
and did not ﬁnd evidence of an interaction between age,
smoking status or cumulative smoking and decreasing telomere
length on risk of COPD classiﬁed as GOLD or as FEV1/FVC
below LLN. For GOLD we found a p value for test of inter-
action of 0.01 for men compared with women (required p value
after Bonferroni correction <0.05/4=0.013). However, the cor-
responding p value for FEV1/FVC below LLN was 0.75.
The results from the two studies separately are shown in
tables S2–S5 and ﬁgures S1–S4 in the online supplement. The
Table 2 Association between telomere length and covariables individually by univariable regression analysis and in combination by
multivariable regression analysis
Univariable Multivariable
Coefficient (95% CI) p Value Coefficient (95% CI) p Value Rank
Age, years −22.1 (−22.7 to −21.4) <1×10−300 −21.5 (−22.2 to −20.8) <1×10−300 1
Male gender −102.1 (−120.1 to −84.1) 1×10−28 −88.8 (−106.0 to −71.6) 4×10−24 2
Cumulative smoking in pack-years −5.2 (−5.6 to −4.8) 4×10−126 −1.4 (−1.9 to −0.9) 3×10−8 3
Body mass index, kg/m2 −13.2 (−15.3 to −11.1) 2×10−33 −5.3 (−7.3 to −3.3) 3×10−7 4
Smoking inhalation −17.2 (−35.3 to −0.8) 0.04 −39.3 (−58.8 to −19.9) 8×10−5 5
<8 years in school −250.7 (−274.3 to −227.1) 2×10−98 −25.9 (−39.3 to −12.4) 2×10−4 6
C-reactive protein, mg/l −8.4 (−10.1 to −6.8) 4×10−23 −2.8 (−4.3 to −1.2) 4×10−4 7
Ever smoking −130.2 (−149.1 to −111.2) 1×10−43 Omitted* – –
Exposure to dust or fumes −66.5 (−92.5 to −40.4) 2×10−7 Omitted* – –
*Omitted by backward elimination of variables (for p<0.1) in stepwise linear regression analysis.
Figure 2 Forced expiratory volume in 1 s (FEV1) % predicted, forced vital capacity (FVC) % predicted and FEV1/FVC by quartiles of telomere
length. Values are shown as mean and SE. Multivariable adjustments include age, gender, body mass index, smoking status, smoking inhalation,
cumulative smoking in pack-years, occupational exposure to dust and fumes, years in school, plasma C-reactive protein levels, grade of dyspnoea
and study.
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two studies showed similar results for all analyses. We repeated
all analyses excluding individuals where a telomere length meas-
urement had been obtained after a rerun of the blood sample.
These sensitivity analyses did not change any of the main results
or conclusions (data not shown).
DISCUSSION
The most important and novel ﬁnding from this observational
study of a large sample of the Danish general population is that,
although short telomere length is associated with reduced lung
function and with an increased risk of COPD, these associations
are attenuated markedly after age and multivariable adjustment.
However, even after multivariable adjustment, a decrease in
telomere length of 1000 base pairs was associated with a
1.07-fold risk of COPD by GOLD criteria as well as by FEV1/
FVC below LLN. Nevertheless, we cannot totally exclude that
this remaining association could simply be a result of residual
confounding. These results demonstrate an effect, albeit small,
of an independent association between reduced telomere length
and the risk of lung disease. It could be argued that telomere
length is a marker of premature ageing and, as such, a mechan-
ism by which other factors such as age, gender and smoking act.
Therefore, telomere length could remain of interest even if not
independently associated with lung function or risk of COPD.
The biological mechanism behind the ﬁnding of an associ-
ation between decreased telomere length and decreased lung
function and increased risk of COPD could be accelerated cell
turnover in individuals with COPD, caused by inﬂammation
and oxidative stress induced by inhalation of factors such as
nitrogen dioxide, ozone, gasoline and diesel exhaust and
tobacco smoke. Another hypothesis is that ageing and exposure
to cigarette smoke entail lymphocyte senescence which increase
susceptibility to infection and eventually lead to the chronic
inﬂammation characteristic of COPD.21 COPD may also be
associated with a genetic predisposition to shorter telomere
length due to decreased telomerase activity, a theory supported
by ﬁndings of shorter telomere length and lower telomerase
activity in cultured pulmonary cells from patients with COPD
Figure 3 Changes in forced expiratory volume in 1 s (FEV1) %
predicted, forced vital capacity (FVC) % predicted and FEV1/FVC for a
1000 base pair decrease in telomere length. Values are shown as mean
and SE. Multivariable adjustments include age, gender, body mass
index, smoking status, smoking inhalation, cumulative smoking in
pack-years, occupational exposure to dust and fumes, years in school,
plasma C-reactive protein levels, grade of dyspnoea and study.
Figure 4 Change in forced expiratory volume in 1 s/forced vital capacity (FEV1/FVC) per 1000 base pair decrease in crude telomere length
according to gender, age, smoking status and cumulative smoking stratiﬁcations. Unadjusted values are shown as mean and SE.
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compared with control subjects.22 23 Also, in a recent study
Alder et al24 examined telomerase null mice with short telo-
meres and found that short telomere length could be a sign of
genetic disposition to emphysema by increasing susceptibility to
cigarette smoke-induced lung damage. Taken together, it is bio-
logically plausible that short telomere length is associated with
reduced lung function and an increased risk of COPD; however,
the precise mechanism is unknown.
Our results are supported by previous ﬁndings of an associ-
ation between telomere length and lung function and risk of
COPD.25–29 Published studies have mainly been case–control
studies of 26–283 COPD cases and 20–155 control subjects. In
our cohort of 6770 individuals with COPD we found a
1.15-fold increased risk of COPD for individuals with the
shortest telomere lengths compared with those with the longest
telomere lengths. To contrast this with previous ﬁndings, Savale
et al25 compared 50 COPD patients with 50 matched control
subjects and found a 28-fold increased risk of COPD for indivi-
duals with short telomere length compared with individuals
with long telomere length. Two other small case–control studies
were unable to show an association between telomere length
and lung function but found an association between smoking
exposure and telomere length.26 27 Mui et al28 also demon-
strated an association between telomere length and lung func-
tion, but this study included COPD cases only. Overall, the
results of previous studies support the notion that short telo-
mere length is associated with decreased lung function and
hence the risk of COPD. The present study of a very large
Figure 5 Logistic regression analysis of risk of chronic obstructive pulmonary disease (COPD) according to telomere length in quartiles.
Multivariable adjustments include age, gender, body mass index, smoking status, smoking inhalation, cumulative smoking in pack-years,
occupational exposure to dust and fumes, years in school, plasma C-reactive protein levels, grade of dyspnoea and study. COPD was deﬁned
either by the Global initiative for chronic Obstructive Lung Disease (GOLD) criteria or by forced expiratory volume in 1 s/forced vital capacity ratio
(FEV1/FVC) below lower limit of normal.
Figure 6 Risk of being classiﬁed as chronic obstructive pulmonary disease (COPD) by the Global initiative for chronic Obstructive Lung Disease
(GOLD) criteria or by forced expiratory volume in 1 s/forced vital capacity (FEV1/FVC) below lower limit of normal (LLN) per 1000 base pair decrease
in telomere length. Multivariable adjustments include age, gender, body mass index, smoking status, smoking inhalation, cumulative smoking in
pack-years, occupational exposure to dust and fumes, years in school, plasma C-reactive protein levels, grade of dyspnoea and study. COPD was
deﬁned either by the GOLD criteria or by FEV1/FVC ratio below LLN.
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sample from a general population suggests that the association is
more moderate than previously reported in smaller case–control
studies.
A strength of our study is the large cohort with telomere
length measurement and spirometry data from 46 396 indivi-
duals from the Danish general population. Also, importantly, we
used two different classiﬁcations of COPD, examining 6770
individuals classiﬁed as COPD by GOLD criteria and 5136 by
FEV1/FVC below LLN, and found similar results for the two
COPD classiﬁcations. In addition, we combined data from two
independent studies to obtain additional power, but the fact that
these studies showed comparable results individually for the
association between short telomeres and decreased lung func-
tion and increased risk of COPD adds additional credibility to
the present study. Finally, the very strong association between
decreasing telomere length and increasing age demonstrates the
quality of our telomere length measurement.
One limitation of our study is that we cannot exclude the
presence of residual confounding, despite the fact that we have
included potential confounders such as age, gender, body mass
index, smoking status, smoking inhalation, cumulative smoking,
occupational exposure to dust and fumes, educational level,
C-reactive protein levels and dyspnoea. Another limitation is
that we did not have information on 6-min walking distance
and therefore were not able to adjust for the entire Body mass
index, airway Obstruction, Dyspnoea, and Exercise capacity
(BODE) Index.30 Nevertheless, we did adjust for the three most
important factors—namely, lung function, body mass index and
grade of dyspnoea. The ﬁnding that the association was only
moderate could also be explained by an underrepresentation of
the most severe cases of COPD in our population, which may
have underestimated the association between short telomere
length and risk of COPD in this present study. Finally, as we
studied white subjects only, our results may not necessarily
apply to other races.
In conclusion, short telomere length is associated with
decreased lung function and with increased risk of COPD,
according to the GOLD classiﬁcation as well as according to
FEV1/FVC below LLN. However, the association seems to be
only moderate and our results stress the importance of adjusting
for age and other confounders when examining the association
between COPD and short telomeres. Whether telomere shorten-
ing per se increases risk of COPD is still an unresolved question
and should be examined in a study designed to evaluate the
causal direction of the association.
Acknowledgements We thank laboratory technician Anja Jochumsen for assisting
with the telomere measurements. The authors are indebted to the staff and
participants in the Copenhagen General Population Study and the Copenhagen City
Heart Study.
Contributors LR, SEB and BGN initiated the study. LR performed statistical
analyses supervised by SEB, JV and BGN. All authors analysed and interpreted the
results. BGN, MW and SEB collected data. LR drafted the manuscript which was
scrutinised by the other authors, all of whom accepted the ﬁnal submitted
manuscript.
Funding This study was ﬁnancially supported by Chief Physician Johan Boserup
and Lise Boserup’s Foundation, the Copenhagen County Foundation, Herlev
Hospital, Copenhagen University Hospital and the Danish Heart Foundation.
Competing interests None.
Patient consent Written informed consent was obtained from all participants.
Ethics approval Ethical approval was obtained from Herlev Hospital and Danish
ethics committees (H-KF01-144/01 and KF100.2039/91).
Provenance and peer review Not commissioned; internally peer reviewed.
REFERENCES
1 Rahman I. The role of oxidative stress in the pathogenesis of COPD: implications for
therapy. Treat Respir Med 2005;4:175–200.
2 Donate LE, Blasco MA. Telomeres in cancer and ageing. Philos Trans R Soc Lond B
Biol Sci 2011;366:76–84.
3 Stewart SA, Weinberg RA. Telomeres: cancer to human aging. Annu Rev Cell Dev
Biol 2006;22:531–57.
4 Shammas MA. Telomeres, lifestyle, cancer, and aging. Curr Opin Clin Nutr Metab
Care 2011;14:28–34.
5 von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem Sci
2002;27:339–44.
6 Cherkas LF, Aviv A, Valdes AM, et al. The effects of social status on biological
aging as measured by white-blood-cell telomere length. Aging Cell 2006;5:361–5.
7 Valdes AM, Andrew T, Gardner JP, et al. Obesity, cigarette smoking, and telomere
length in women. Lancet 2005;366:662–4.
8 von Zglinicki T, Martin-Ruiz CM. Telomeres as biomarkers for ageing and
age-related diseases. Curr Mol Med 2005;5:197–203.
9 Cassidy A, De Vivo I, Liu Y, et al. Associations between diet, lifestyle factors, and
telomere length in women. Am J Clin Nutr 2010;91:1273–80.
10 Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management
and prevention of chronic obstructive pulmonary disease, GOLD executive summary.
Am J Respir Crit Care Med Published Online First: 9 Aug 2012. doi: 10.1164/
rccm.201204-0596PP
11 Swanney MP, Ruppel G, Enright PL, et al. Using the lower limit of normal for the
FEV1/FVC ratio reduces the misclassiﬁcation of airway obstruction. Thorax
2008;63:1046–51.
12 Baekvad-Hansen M, Dahl M, Tybjaerg-Hansen A, et al. Surfactant protein-B
121ins2 heterozygosity, reduced pulmonary function, and chronic obstructive
pulmonary disease in smokers. Am J Respir Crit Care Med 2010;181:17–20.
13 Dahl M, Bowler RP, Juul K, et al. Superoxide dismutase 3 polymorphism associated
with reduced lung function in two large populations. Am J Respir Crit Care Med
2008;178:906–12.
14 Nordestgaard BG, Palmer TM, Benn M, et al. The effect of elevated body mass
index on ischemic heart disease risk: causal estimates from a Mendelian
randomisation approach. PLoS Med 2012;9:e1001212.
15 Dahl M, Tybjaerg-Hansen A, Lange P, et al. Change in lung function and morbidity
from chronic obstructive pulmonary disease in alpha1-antitrypsin MZ heterozygotes:
a longitudinal study of the general population. Ann Intern Med 2002;136:270–9.
16 Juul K, Tybjaerg-Hansen A, Mortensen J, et al. Factor V leiden homozygosity,
dyspnea, and reduced pulmonary function. Arch Intern Med 2005;165:2032–6.
17 Kaur-Knudsen D, Nordestgaard BG, Bojesen SE. CHRNA3 genotype, nicotine
dependence, lung function and disease in the general population. Eur Respir J
2012;40:1538–44.
18 Cawthon RM. Telomere length measurement by a novel monochrome multiplex
quantitative PCR method. Nucleic Acids Res 2009;37:e21.
19 Weischer M, Bojesen SE, Cawthon RM, et al. Short telomere length, myocardial
infarction, ischemic heart disease, and early death. Arterioscler Thromb Vasc Biol
2012;32:822–9.
20 Bestall JC, Paul EA, Garrod R, et al. Usefulness of the Medical Research Council
(MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive
pulmonary disease. Thorax 1999;54:581–6.
21 Aoshiba K, Nagai A. Senescence hypothesis for the pathogenetic mechanism of
chronic obstructive pulmonary disease. Proc Am Thorac Soc 2009;6:596–601.
22 Amsellem V, Gary-Bobo G, Marcos E, et al. Telomere dysfunction causes sustained
inﬂammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med
2011;184:1358–66.
23 Tsuji T, Aoshiba K, Nagai A. Alveolar cell senescence in patients with pulmonary
emphysema. Am J Respir Crit Care Med 2006;174:886–93.
24 Alder JK, Guo N, Kembou F, et al. Telomere length is a determinant of emphysema
susceptibility. Am J Respir Crit Care Med 2011;184:904–12.
25 Savale L, Chaouat A, Bastuji-Garin S, et al. Shortened telomeres in circulating
leukocytes of patients with chronic obstructive pulmonary disease. Am J Respir Crit
Care Med 2009;179:566–71.
26 Houben JM, Mercken EM, Ketelslegers HB, et al. Telomere shortening in chronic
obstructive pulmonary disease. Respir Med 2009;103:230–6.
27 Morla M, Busquets X, Pons J, et al. Telomere shortening in smokers with and
without COPD. Eur Respir J 2006;27:525–8.
28 Mui TS, Man JM, McElhaney JE, et al. Telomere length and chronic obstructive
pulmonary disease: evidence of accelerated aging. J Am Geriatr Soc
2009;57:2372–4.
29 Lee J, Sandford AJ, Connett JE, et al. The relationship between telomere length and
mortality in Chronic Obstructive Pulmonary Disease (COPD). PLoS One 2012;7:
e35567.
30 Celli BR, Cote CG, Marin JM, et al. The body-mass index, airﬂow obstruction,
dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N
Engl J Med 2004;350:1005–12.
Rode L, et al. Thorax 2013;68:429–435. doi:10.1136/thoraxjnl-2012-202544 435
Chronic obstructive pulmonary disease
